Vir Biotechnology, Inc. $VIR Shares Sold by Citigroup Inc.

Citigroup Inc. reduced its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 22.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 323,525 shares of the company’s stock after selling 92,426 shares during the quarter. Citigroup Inc. owned approximately 0.23% of Vir Biotechnology worth $1,847,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ARCH Venture Management LLC acquired a new position in shares of Vir Biotechnology in the 2nd quarter worth approximately $65,100,000. Orbimed Advisors LLC raised its position in shares of Vir Biotechnology by 5.9% during the 2nd quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock valued at $11,999,000 after acquiring an additional 132,466 shares in the last quarter. Aberdeen Group plc lifted its stake in Vir Biotechnology by 51.6% during the third quarter. Aberdeen Group plc now owns 1,526,265 shares of the company’s stock worth $8,715,000 after purchasing an additional 519,374 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Vir Biotechnology by 43.6% during the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after purchasing an additional 225,544 shares during the last quarter. Finally, Nordea Investment Management AB boosted its holdings in Vir Biotechnology by 1.4% in the third quarter. Nordea Investment Management AB now owns 714,561 shares of the company’s stock worth $3,930,000 after purchasing an additional 10,184 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: HC Wainwright materially raised its FY2026 outlook (now -$0.81 vs prior -$2.16) and flipped Q2 2026 to a $0.73 EPS forecast, signaling expectations for much stronger near‑term results; the firm retained a “Buy” rating and $20 price target.
• Positive Sentiment: HC Wainwright also nudged several 2026 quarterly estimates higher (Q3/Q4 2026 less negative), which supports the narrative of improving near‑term fundamentals and likely helped lift sentiment.
• Positive Sentiment: Management change: Vir named CEO Marianne De Backer as President, expanding her responsibilities — a governance move that can be read as streamlining decision‑making and execution. Vir Biotechnology Names CEO Marianne De Backer as President
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $20 target — a supportive endorsement but already priced in by some investors given previous coverage.
• Negative Sentiment: HC Wainwright trimmed longer‑term forecasts: FY2027 was lowered (to -$1.99 from -$1.90) and FY2028/FY2029 estimates were reduced (e.g., FY2028 to -$1.65 from -$1.40; FY2029 to -$1.24 from -$1.13), reflecting weaker medium‑term profitability expectations that could cap upside if sustained.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on VIR shares. HC Wainwright increased their target price on shares of Vir Biotechnology from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Barclays boosted their price objective on shares of Vir Biotechnology from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Tuesday, February 24th. Evercore reiterated an “outperform” rating and set a $18.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, February 24th. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.44.

Vir Biotechnology Stock Performance

Shares of VIR opened at $9.55 on Monday. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $10.94. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -3.02 and a beta of 1.65. The firm has a fifty day moving average of $7.34 and a 200-day moving average of $6.27.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million for the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The business’s revenue for the quarter was up 417.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.76) earnings per share. Analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $9.51, for a total transaction of $209,220.00. Following the sale, the director owned 1,122,391 shares of the company’s stock, valued at $10,673,938.41. The trade was a 1.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Verneuil Vanina De sold 13,700 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $9.82, for a total value of $134,534.00. Following the transaction, the executive vice president owned 112,982 shares of the company’s stock, valued at $1,109,483.24. This trade represents a 10.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 177,546 shares of company stock worth $1,522,174 in the last three months. 16.00% of the stock is owned by company insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.